-
Mashup Score: 0Novel Anti-Estrogen Therapies Are Poised to Expand Treatment Options in Advanced ER+ Breast Cancer - 7 hour(s) ago
Seth Wander, MD, PhD on novel anti-estrogen therapies that could expand treatment options in estrogen receptor–positive advanced breast cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 7Northwestern University Nervous System Tumor Bank - 3 day(s) ago
The Northwestern University Nervous System Tumor Bank provides scientists with high-quality, patient-derived biospecimens to support preclinical and translational neuro-oncology research.
Source: www.feinberg.northwestern.eduCategories: General Medicine News, Oncologists1Tweet-
Sending a virtual cheer to our teams collaborating across @NorthwesternMed! Learn about Northwestern University Nervous System Tumor Bank, supporting preclinical and translational neuro-oncology research: https://t.co/nfyI9KRNoF @NUFeinbergMed #BTSM https://t.co/wi8OCCgvDp
-
-
Mashup Score: 6Eflornithine Plus Lomustine Demonstrates Clinically Meaningful Survival Benefits in Grade III IDH-Mutant Astrocytoma - 10 day(s) ago
Rimas V. Lukas, MD, discusses the potential role for eflornithine plus lomustine in recurrent grade 3 IDH-mutant astrocytoma.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
The addition of eflornithine to SOC lomustine did significantly improve OS and PFS vs lomustine for a subgroup of patients with recurrent grade 3, IDH-mutant astrocytoma per the 2021 WHO diagnostic criteria. @BrainTumorInst #btsm https://t.co/hYOO7Ad3lI https://t.co/JNh1UXQtDI
-
-
Mashup Score: 6Eflornithine Plus Lomustine Demonstrates Clinically Meaningful Survival Benefits in Grade III IDH-Mutant Astrocytoma - 11 day(s) ago
Rimas V. Lukas, MD, discusses the potential role for eflornithine plus lomustine in recurrent grade 3 IDH-mutant astrocytoma.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
The addition of eflornithine to SOC lomustine did significantly improve OS and PFS vs lomustine for a subgroup of patients with recurrent grade 3, IDH-mutant astrocytoma per the 2021 WHO diagnostic criteria. @BrainTumorInst #btsm https://t.co/hYOO7Ad3lI https://t.co/JNh1UXQtDI
-
-
Mashup Score: 0
Treatment with vorasidenib also confers better seizure control than placebo in the phase 3 INDIGO study.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
At a median follow-up of 20.1 months, the median PFS with vorasidenib was NE (95% CI, 22.1-NE) by BICR assessment vs 11.4 months (95% CI, 11.1-13.9) with placebo. #btsm https://t.co/nqe9Xcgrqh
-
-
Mashup Score: 0IDH Inhibitors in the Treatment of Low-Grade Gliomas - 20 day(s) ago
Panelists discuss how IDH inhibitors such as ivosidenib could potentially reshape the treatment approach for low-grade gliomas, while also exploring what further clinical evidence would be necessary to confidently integrate these novel agents into standard care protocols.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
Panelists discuss how IDH inhibitors such as ivosidenib could potentially reshape the treatment approach for low-grade gliomas. #btsm | @VPuduvalli https://t.co/DMFxW2NczV
-
-
Mashup Score: 1Virus Therapy Gets Orphan Drug Designation for Glioma Treatment - 1 month(s) ago
The FDA granted an orphan drug designation to herpes simplex virus type 1 (HSV-1) oncolytic virus MB-108 for malignant glioma treatment.
Source: www.oncnursingnews.comCategories: General Medicine News, Oncologists1Tweet-
The FDA granted an Orphan Drug Designation to MB-108, a second-generation herpes simplex virus type 1 (HSV-1) oncolytic virus for malignant glioma. #BTSM https://t.co/nm2iwFQ061
-
-
Mashup Score: 0PET Imaging Agent Earns FDA Priority Review in Recurrent Glioma - 2 month(s) ago
The FDA has set a Prescription Drug User Fee Act date of April 26, 2025, for TLX101-CDx as an imaging agent for patients with glioma.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
The FDA has granted priority review to TLX101-CDx for use as a PET imaging agent for progressive or recurrent glioma. #btsm | @US_FDA https://t.co/jctym178jQ
-
-
Mashup Score: 5Novel Anti-Estrogen Therapies Are Poised to Expand Treatment Options in Advanced ER+ Breast Cancer - 2 month(s) ago
Seth Wander, MD, PhD on novel anti-estrogen therapies that could expand treatment options in estrogen receptor–positive advanced breast cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Seth Wander, MD, PhD, on novel anti-estrogen therapies that could expand treatment options in estrogen receptor–positive advanced breast cancer. @MGHCancerCenter #btsm https://t.co/pAs5CZNtWl
-
-
Mashup Score: 1
Raymond B. Mailhot, MD, MPH, discussed methods for comparing academic performances of patients following radiation therapy with healthy control groups.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
Raymond B. Mailhot, MD, MPH, discussed methods for comparing academic performances of patients following radiation therapy with healthy control groups. #btsm | @raymailhotvega https://t.co/gIj6xwBBok
-
Seth Wander, MD, PhD, on novel anti-estrogen therapies that could expand treatment options in estrogen receptor–positive advanced breast cancer. @MGHCancerCenter #btsm https://t.co/pAs5CZNtWl